Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2619)	10/12/2009 10:18:19 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MRNA opened with a good UG and is still up is 37.9% on volume of > 2,205,000 about 8x its ADV bigcharts.marketwatch.com It presented today new in vivo data demonstrating continued progress in its oncology program. As previously mentioned, MRNA had been trimming its losses and on April 2 it announced that it had sold its Manufacturing Business to Par Pharmaceuticals and was concentrating on its RNAi projects. Its CEO, Michael French said: "that agreement eliminates all of MDRNA's non-RNAi expenses and represents the final step in the plan to create a company solely focused in the research and development of RNAi-based therapeutics." I think that I will keep my target around $4.50 unchanged.<g> bigcharts.marketwatch.com Bernard